TABLE 1.
CCR5 coreceptor usage of primary HIV-2 isolates
| Isolate | Country | Clinical statusa | Subtype (env) | Infectibility of PBMCsb
|
MT-2 syncytia (day 10)c | |
|---|---|---|---|---|---|---|
| CCR5 +/+ | CCR5 −/− | |||||
| A1958 | Senegal | AIDS | A | >784 | 0 | — |
| A2267 | Senegal | Asymptomatic | A | 522 | 0 | — |
| SLRHC | Guinea-Bissau | Asymptomatic | Ad | 801 | 0 | — |
| A2270 | Senegal | Asymptomatic | A | 481 | 0 | — |
| 310072 | Ivory Coast | Blood donor | B | 250 | 0 | — |
| 310340 | Ivory Coast | Blood donor | NDe | >784 | 0 | — |
| 60415K | Senegal | Asymptomatic | Ad | >784 | 0 | — |
| 7312A | Ivory Coast | Lymphadenopathy | A/Bf | 503 | 79 | + |
| GB87 | Guinea-Bissau | Hospitalized TB patient | A | 100 | 250 | + |
| 310248 | Ivory Coast | Blood donor | A | 270 | 55 | + |
| 310342 | Ivory Coast | Blood donor | ND | >784 | 513 | + |
| 310319 | Ivory Coast | Blood donor | B | 383 | 154 | ++ |
| 7924A | Guinea-Bissau | AIDS | Ad | 99 | 96 | ++ |
| 77618 | Ivory Coast | AIDS | A | 193 | 100 | ++ |
| GB122 | Guinea-Bissau | AIDS | A | 110 | 174 | +++ |
a
For blood donors, actual clinical status is unknown. TB, tuberculosis.
b
Results are based on two independent experiments, and the values given are nanograms of p27 antigen per milliliter from day 14 of one representative experiment.
c
—, no visible syncytia; +, ++, and +++, increasing numbers of syncytia relative to cultures with + designation.
d
Subtype was determined based on sequence analysis of two different genome regions (i.e., gag [31]) or the primer binding site (data not shown).
e
ND, not determined.
f
A/B recombinant (based on full-length genome).